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Prophylaxis with high doses of neutralizing antibody typically offers protection against challenge with viruses
producing acute infections. In this study, we have investigated the ability of the neutralizing human monoclonal
antibody, KZ52, to protect against Ebola virus in rhesus macaques. This antibody was previously shown to fully protect
guinea pigs from infection. Four rhesus macaques were given 50 mg/kg of neutralizing human monoclonal antibody
KZ52 intravenously 1 d before challenge with 1,000 plaque-forming units of Ebola virus, followed by a second dose of
50 mg/kg antibody 4 d after challenge. A control animal was exposed to virus in the absence of antibody treatment.
Passive transfer of the neutralizing human monoclonal antibody not only failed to protect macaques against challenge
with Ebola virus but also had a minimal effect on the explosive viral replication following infection. We show that the
inability of antibody to impact infection was not due to neutralization escape. It appears that Ebola virus has a
mechanism of infection propagation in vivo in macaques that is uniquely insensitive even to high concentrations of
neutralizing antibody.
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Introduction
Editor’s note: The potential efﬁcacy of pre- and post-exposure
prophylaxis against Ebola virus infection, as well as the fundamentally
important question of whether neutralizing bodies are important for
Ebola virus resistance, is addressed by a related manuscript in this
issue of PLoS Pathogens. Please see doi:10.1371/journal.
ppat.0030002 by Feldmann et al.
Passive transfer of relatively high concentrations of
neutralizing antibodies can protect against challenge with a
range of viruses in animal models and in humans [1–3].
Protection in some cases is in the form of sterilizing
immunity, i.e., no viral replication is observed following
challenge [2,4,5]. In other cases (e.g., [5,6]), some replication is
observed but protection from disease is achieved, presumably
because neutralizing antibody sufﬁciently blunts infection for
T cell and innate immunity to resolve infection [7]. It might
be expected that passive neutralizing antibody would be most
effective against challenge with acute viruses. Many acute
viral infections are resolved even in the absence of neutraliz-
ing antibody, and the blunting effect of passive antibody
would provide more time for the development of effective
cellular immune responses. In contrast, chronic viruses may
present a greater challenge to passive antibody, since, in the
absence of sterilizing immunity, there is a window of
opportunity for the virus to establish a chronic infection
before cellular immunity can be mobilized.
Ebola virus (EBOV) causes a severe acute infection in
humans [8]. Infection with the Ebola Zaire strain, Zaire
ebolavirus (ZEBOV), produces mortality in the range of 60%–
90% [9] with death generally occurring around 7–11 d
following the appearance of symptoms [8]. There is a single
report describing the use of convalescent sera to treat EBOV
infection [10]. However, the patients in this report may have
already been through the worst stages of the disease, and it is
not clear that serum antibodies were responsible for their
recovery[10]. Further,neutralizing antibody titers insurvivors
of EBOV infection tend to be rather low, although we have
isolated a neutralizing human monoclonal antibody (mAb),
KZ52, of good potency from a convalescent individual [11].
The ability of passive antibody to protect against EBOV has
been investigated in a number of animal models. The guinea
pig and mouse models use EBOVs that have been serially
passaged to adapt to replication in the respective animals and
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guinea pig model using neutralizing horse, sheep, and goat
immunoglobulin G (IgG) against EBOV [12,13] and the human
anti-EBOV GP mAb, IgG KZ52. This antibody neutralizes
ZEBOV (1995, Kikwit) with a 50% inhibitory concentration
(IC50) of 0.05–0.3 lg/ml and an IC90 of 0.5–2.6 lg/ml in Vero
cells [11,14] and an IC50 of approximately 0.05–1 lg/ml and a
IC90 of 0.5–2 lg/ml in primary human monocytes/macro-
phages [14]. We showed that when administered subcuta-
neously at a dosage of 25 mg/kg up to 1 h after challenge, the
antibody protects against robust ZEBOV challenge (10,000
plaque-forming units [pfu]) in the guinea pig model [6].
Macaques provide a model of EBOV infection that is likely
closer to human infection. The human virus can be used
directly in macaques without need for adaptation and the
course of disease mirrors that seen in humans [8]. In
cynomolgus macaques (Macaca fascicularis), ZEBOV infection
produces a mortality rate of 100% with death occurring 6–8 d
following infection with 1,000 pfu [15], while in rhesus
macaques (Macaca mulatta) ZEBOV produces about 100%
mortality with death occurring 7–10 d after infection with
1,000 pfu [16]. In contrast to the guinea pig experiments, the
passively transferred polyclonal equine neutralizing IgG
described above provided only some minor beneﬁt in the
form of a slight delay in the onset of viremia from day 5 to
day 7 [13] following ZEBOV challenge of cynomolgus
monkeys. No signiﬁcant reduction in mortality was observed.
However, protection against EBOV in primates has been
observed in a low dose challenge model. Thus, neutralizing
equine IgG protected baboons from ,30 LD50 (50% lethal
dose) ZEBOV challenge when the IgG was given up to 1 h
after infection and the serum contained high neutralizing
antibody titers (1:128 to 1:512) [17,18], and, similarly,
neutralizing ovine serum protected baboons against 0.6
LD50 ZEBOV challenge [19].
Here, we studied the ability of passively transferred
neutralizing human mAb KZ52 to protect against ZEBOV
challenge in rhesus macaques. This passive transfer failed to
protect the macaques against challenge with ZEBOV, and,
furthermore, had a minimal effect on the explosive viral
replication following infection. We showed by ELISA that
antibody was present at high levels in serum of the monkeys
and that neutralization escape was not responsible for the
resistance of virus to antibody prophylaxis.
Results
Plasma Viremia in Antibody-Treated Macaques
To evaluate whether IgGl KZ52 could protect against Ebola
virus infection in a nonhuman primate animal model,
antibody was passively transferred to rhesus macaques
followed by challenge with the 1995 ZEBOV (Kikwit) isolate
24 h later. Protection against virus challenge by neutralizing
antibodies in naive animals often requires high doses of
antibody [2]. Therefore, we used a high dose of 50 mg/kg
KZ52, which was close to the maximum practically achievable.
In addition, we gave a second bolus of 50 mg/kg of KZ52 on
day 4 following infection. The results for the four antibody-
treated animals show a steady increase in plasma viremia up
to 10
5–10
7 pfu/ml on day 7 (Figure 1). These levels of plasma
viremia closely parallel those seen in the control animal and
typically seen in historical controls [15]. The second bolus of
antibody given on day 4 did not appear to have any impact
upon the rate of increase of plasma virus (Figure 1). Three of
the treated animals were euthanized when moribund at day 9
or 10 post infection. The fourth treated animal showed a
decrease in plasma viral load after the peak and survived to
day 28 before becoming moribund when it too was
euthanized. Although monkey CH46 had less severe symp-
toms than the other animals in the study, it was concluded
that this animal, too, was suffering from disease due to
ZEBOV, as evidenced, for example, by copious Ebola virus
antigen in the lungs (see below).
Serum Antibody Levels in Treated Animals
Serum antibody (KZ52) loads were measured 1 d before
virus challenge (day  1) and 4 d after challenge but before
antibody boosting (day 4) by an ELISA designed to detect
KZ52 as a human antibody that has bound to immobilized
ZEBOV glycoprotein. The serum KZ52 antibody levels on day
4 were in the approximate range 200–400 lg/ml (Table 1). The
Figure 1. Plasma Viremia in Macaques Challenged with ZEBOV
Shown is the measured viremia, in log10 pfu per ml, for four antibody-
treated monkeys (CH46, CH56, CH57, and CH83) and one untreated
control animal (EHD) at days 4, 7, 9, and 10 in plasma by plaque assay as
described in Materials and Methods. 50 mg/kg of KZ52 IgG1 human
antibody [11] was given intravenously to four rhesus macaques 1 d
before and again 4 d after challenge with 1,000 pfu (intramusculary) of
the 1995 ZEBOV (Kikwit) isolate. Ab, antibody.
doi:10.1371/journal.ppat.0030009.g001
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Author Summary
Ebola virus is one of the most feared of human pathogens with a
mortality that can approach 90% and an extremely rapid disease
course that can lead to death within days of infection. Antibodies
able to inhibit viral infection in culture, neutralizing antibodies, can
typically prevent viral infection in animals and humans when
present prior to infection, at sufficient concentration. Such
neutralizing antibodies may be provided through passive admin-
istration or induced by vaccination. We have previously shown that
a human neutralizing antibody can protect guinea pigs against
Ebola virus. However, here we show that this antibody does not
protect monkeys against Ebola virus and surprisingly appears to
have very little impact upon the rapid course of infection, despite
being present at very high levels in the blood of the monkeys. We
conclude that administering antibody prior to or immediately
following exposure to Ebola virus, for example, after an accident in a
research setting or a bioterrorist attack, is unlikely to be effective in
preventing disease. Recent successes in protecting monkeys against
Ebola virus through vaccination may be independent of antibody,
or, more likely, critically dependent on the cooperation of antibody
and cellular immunity.two control monkeys, EHD (untreated and challenged), and a
negative monkey (neither treated nor challenged), had very
similar background levels of reactivity to the glycoprotein
and anti-human antibody as each of the treated monkeys
before treatment. A 50-mg/kg dose typically produces serum
mAb concentrations in animals on the order of 500 lg/ml
after injection [6]. Since the neutralization titer of KZ52
(IC90) for ZEBOV is on the order of 0.5–2.5 lg/ml, depending
upon the target cell and the presence of complement, the
concentrations of KZ52 in the animals at the time of
challenge and for the ﬁrst few days were, as expected, greater
than, or on the order of 100 3 IC90. These concentrations
typically provide sterilizing immunity against challenge by a
number of viruses [4,20].
Antibody Neutralization of Plasma Virus from Treated
Animals
One formal possibility is that the neutralizing antibody has
little effect on the course of infection in the treated monkeys
because of the rapid emergence of neutralization escape
mutants. Accordingly, virus was isolated from a selection of
plasma from day 4 (monkeys CH56, CH57, and CH83) and day
7 (monkeys CH56 and CH57). All of these viruses were
sensitive to KZ52 so that essentially 100% neutralization was
observed in vitro at 40 and 400 lg/ml KZ52 in a plaque assay
(see Materials and Methods) using Vero E6 target cells.
Virus Levels in Different Organs and
Immunohistochemistry
In order to gain a better understanding of any differences
in pathology between the control and antibody-treated
animals, the levels of virus in different organs were surveyed
postmortem. Viral levels in the liver, spleen, kidney, adrenal
glands, lung, and mesenteric and inguinal lymph nodes were
high (10
4–10
6 pfu/g) in the control and three of the four
treated animals (Table 2). However, monkey CH46, who
survived much longer than the other animals (to day 28)
showed some major histopathological differences from the
other infected monkeys and from the norm for ZEBOV
infection [15]. Relatively low viral levels were observed in
most of the organs of CH46, and none in the liver, spleen, and
adrenal glands. In addition, large immunoreactive monocytes
were found in the blood of monkeys CH56, CH57, and CH83,
but not in CH46 (Figure 2). Typically, smaller immunor-
eactive monocytes are seen with ZEBOV infection [15]. The
presence of large immunoreactive monocytes may simply
reﬂect uptake of antibody-coated virions via Fc receptors and
subsequent viral clearance. However, it is interesting to note
that previous studies have implicated mononuclear phag-
ocytes as vehicles for transport of ﬁlovirus particles to
speciﬁc organs such as liver and spleen [21–24]. If virus
particles could remain infectious following Fc receptor-
mediated uptake in a subset of cells (compare DC-SIGN
mediated uptake of HIV-1 by dendritic cells [25]), then the
course of disease in monkeys CH56, CH57, and CH83 might
represent the net result of inhibition by neutralization and
enhancement by antibody-mediated cellular uptake. Interest-
ingly, monkey CH46, who fared somewhat better than the
others and lacked virus in the liver and spleen, did not show
the presence of large immunoreactive monocytes. This is
suggestive of lowered Fc receptor-mediated uptake of virus or
reduced activity of the mononuclear phagocytic system.
Discussion
Here, we describe the case of a potent neutralizing human
monoclonal antibody, administered to give a high serum
concentration, which is shown to be unable to protect
macaques against challenge with a lethal dose of ZEBOV.
The antibody appeared to have very little effect on the course
of virus replication or disease in three of four treated
animals. Neutralization escape does not appear to explain the
lack of protection observed by the antibody. In one animal, a
more limited infection was observed, but this macaque did
also eventually succumb to the effects of viral disease.
The challenge dose of 1,000 pfu used corresponds to the
amount of EBOV contained in a relatively small quantity of
ﬂuid (on the order of 1 ll) from an infected individual given
Table 1. Human KZ52 Antibody Titers in Rhesus Macaques Pre-
Treatment 1 d before Challenge with ZEBOV (Day  1) and Pre-
Boost 4 d after Challenge with ZEBOV (Day 4)
Monkey Number Day  1( lg/ml) Day 4 (lg/ml)
CH83 0 232
CH57 0 305
CH56 0 334
CH46 0 387
doi:10.1371/journal.ppat.0030009.t001
Table 2. Posthumous Viral Loads in Specific Organs of Rhesus Macaques
Monkey
Number
Treatment Death/
Days Post Infection
Liver
(log10pfu/g)
a
Spleen Kidney Adrenal
Glands
Lung Mes
Lnode
b
Ing
Lnode
b
EHD None 9 5.12 5.18 3.81 4.41 4.19 5.33 5.04
CH83 KZ52 10 5.89 5.55 4.95 6.29 5.11 4.21 5.42
CH57 KZ52 9 5.84 5.50 5.21 5.03 5.49 4.06 5.11
CH56 KZ52 9 5.87 6.13 5.33 4.86 5.58 4.95 5.32
CH46 KZ52 28 0.00 0.00 2.70 0.00 5.26 2.70 3.65
Blue text indicates no viral load; red text, low viral load.
aViral loads are indicated in logarithmic units of pfu/g. Values above 4.5 log10 pfu/g are considered acute.
bMes Lnode, mesenteric lymph node; Ing Lnode, inguinal lymph node.
doi:10.1371/journal.ppat.0030009.t002
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Anti-Ebola Antibody Activity In Vivothe high titers of virus typically found in such individuals (on
the order of 10
6 pfu/ml of blood, for example). Therefore, the
challenge dose was not unreasonable in terms of a natural
exposure to virus.
The negative results with passive antibody contrast strongly
with recent successes in preventing EBOV infection in
macaques through vaccination [26,27]. Does this mean that
neutralizing antibody is unimportant in vaccine protection?
The answer to this question must await further studies.
However, a plausible hypothesis to explain all the data would
still allow for an important contribution of antibody to
vaccine protection. This hypothesis would argue that passive
antibody is unable to completely block all EBOV entry to
cells, and once a few cells are infected, virus replication is so
explosive that it cannot be contained by a de novo generated
cellular immune response. Vaccination, on the other hand,
will provide CD8þ memory T cells that can be rapidly
recruited to become effector cells and limit infection.
Certainly, although mAb KZ52 was able to provide protection
from disease following ZEBOV challenge in the guinea pig
model, immunity was not sterilizing and some viral repli-
cation was noted [6]. Since 1 pfu of EBOV is a lethal dose for
primates [8], a failure of passive antibody to achieve
sterilizing immunity may be critical. Immunohistochemistry,
as discussed above, gives some intriguing hints that uptake of
antibody-coated virions by monocytes may possibly have a
role to play in the course of infection following antibody
treatment. We note, however, that previous in vitro studies
using isolated human monocytes/macrophages did not ﬁnd
evidence of infectivity-enhancing antibodies [14]. More
detailed in vitro and in vivo investigations will be required
before any ﬁrm conclusions can be drawn. We also note that
our experiments were carried out with a single neutralizing
monoclonal antibody. It is possible that a more favorable
outcome may have been apparent for a combination of
neutralizing antibodies or even a combination of neutralizing
and nonneutralizing antibodies [2]. However, these possibil-
ities should be weighed against the very high concentrations
of neutralizing monoclonal antibody used in the experiments
and the efﬁcacy of the antibody in the guinea pig model.
In summary, the inability of high concentrations of
neutralizing antibody to even slow viral replication in
infected macaques is remarkable and implies a mechanism
of infection propagation that is virtually insensitive to
antibody. Overall, the results suggest that monoclonal anti-
body prophylaxis or post-exposure prophylaxis alone are
unlikely to be effective strategies in protecting against EBOV,
for example, following a needle-stick accident in a research
setting or a bioterrorist attack.
Materials and Methods
Passive transfer experiment. 50 mg/kg of KZ52 IgG1 human
antibody [11] was given intravenously to rhesus macaques (weight,
3.9–4.4 kg) 1 d before challenge (day 0) with 1,000 pfu intramuscularly
of the 1995 ZEBOV (Kikwit) isolate and again 4 d later (day þ4). One
monkey was not given any antibody treatment. The animals were
carefully monitored for signs of disease, and Ebola virus plasma
viremia was determined at days 4, 7, 9, and 10 in serum by plaque
assay as described below.
The investigators adhered to the Guide for the Care and Use of
Laboratory Animals when conducting research, using animals [28]. The
United States Army Medical Research Institute of Infectious Diseases
(USAMRIID) animal facilities and animal care and use program are
accredited by the Association for Assessment and Accreditation of
Laboratory Animal Care International. All infectious material and
animals were handled in a maximum-containment biosafety level 4
facility at USAMRIID under standard operating conditions.
Antibody puriﬁcation. IgGl KZ52 was produced and puriﬁed as
described by Parren et al. [29] and was .98% pure, as determined by
sodium dodecyl sulfate-polyacrylamide gel electrophoresis and
contained ,1 IU of endotoxin/ml, as determined in a quantitative
chromagenic Limulus amoebecyte lysate assay (BioWhittaker, Cam-
brex, http://www.cambrex.com).
Viremia determined by plaque assay. Plasma viremia and viral
loads in organs was determined by virus titration in a conventional
plaque assay on Vero E6 cells, as described elsewhere [13,21].
Neutralization assay. Samples were diluted into Eagle’s minimal
essential medium (EMEM; Invitrogen, http://www.invitrogen.com)
with 5% heat-inactivated fetal bovine serum (FBS). In the presence
and absence of a constant dilution of 1:10 or 1:100 of 4 mg/ml KZ52
(thus, 0.4 mg/ml or 0.04 mg/ml), plasma were titrated from 10
 1 to
10
 6 dilutions. Viremia was determined by counting pfu on Vero E6
cell monolayers. Cells grown to conﬂuence in 6-well plates were given
0.2 ml of plasma with and without additional KZ52. The titrated
samples were incubated in the presence of KZ52 for 1 h at 37 8Ci n
5% CO2. After absorption, the cells were overlaid with 2 ml of EMEM
containing 5% FBS, 25 mM HEPES buffer, 50-lg gentamicin per ml,
and 1% agarose. After 10 d, plaques were visible and the cells were
removed from the humidiﬁed 37 8C incubator to visualize plaques
with an inverted phase microscope. 2 ml of neutral red (1:6,000 ﬁnal
concentration; Sigma-Aldrich, http://www.sigmaaldrich.com) was
added to each well, and after an additional 24-h incubation, the
plaques were counted [11,30].
ELISA. Nunc-Immuno Maxisorp enzyme-linked immunosorbent
assay (ELISA) plates (Nunc, http://nuncbrand.com) were coated with
100 ll/well of 10 lg/ml lectin from Galanthus Nivalis (Sigma-Aldrich)
in PBS and incubated overnight at 4 8C. The plates were then blocked
in phosphate-buffered saline (PBS) containing 10% FBS for 2 h. The
wells were then washed twice with wash buffer, PBS containing 0.2%
Tween 20 (Sigma-Aldrich). 293 c e l l sw e r et r a n s f e c t e dw i t ha
mammalian expression plasmid coding for transmembrane domain-
deleted Ebola glycoprotein. Supernatant (100 ll) from these cells,
which contains 0.8–1.3 mg/ml total protein, was used to coat each well
for 1 h at room temperature (RT) after the blocking solution was
removed from the ELISA plates. Plates were then washed six times
with wash buffer. Monkey sera were added in 10-fold dilutions from
1:10 to 1:10
5 in dilution buffer (PBS containing 1% BSA and 0.02%
Tween) and incubated at RT for 1 h. The wells were then washed six
times, and a secondary antibody alkaline phosphatase-conjugated
goat anti-human immunoglobulin G (IgG) against the F(ab9)2 portion
of the antibody (Pierce, http://www.piercenet.com) diluted 1:500 was
added, and this was incubated for 1 h. Finally, the plates were washed
again six times and developed by one tablet of phosphatase substrate
Figure 2. A Large Immunoreactive Monocyte Is Observed in a Blood
Vessel in the Kidney of Monkey CH57 Postmortem
Similar cells were observed in analysis of monkeys CH83 and CH56.
Typically smaller immunoreactive monocytes are seen with ZEBOV
infection [15]. Immunohistochemistry was performed as described in
Materials and Methods.
doi:10.1371/journal.ppat.0030009.g002
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Anti-Ebola Antibody Activity In Vivo(Sigma-Aldrich) in 5 ml of alkaline phosphatase stain buffer (pH 9.8)
per plate. The assay was performed as per manufacturer’s directions.
The plates were read at an optical density of 405 nm on a microplate
reader (Molecular Devices, http://www.moleculardevices.com) at 30
min after adding substrate. A panel of normal sera was run each time
the assay was performed.
Immunohistochemistry. Sections were pretreated with Dako Ready
to Use Proteinase K (Dako, http://www.dako.com) for 6 min at RT
after deparafﬁnization and rehydration through a series of graded
ethanols. Blocking was performed with Dako’s Serum-Free Protein
Block for 20 min pre-antibody exposure. The tissue sections were
then incubated overnight at 4 8C in primary antibody using an equal
mixture of mouse monoclonal antibodies to EBOV GP and VP40
(1:5,000). An alkaline phosphatase-labeled polymer (Dako Envision
System, alkaline phosphatase) was incubated on the sections for 30
min, and then color was developed by exposing tissue to 6-bromo-2-
hydroxyl-3-naphtholic acid (HistoMark Red; Kikegaard and Perry
Laboratories, http://www.kpl.com) substrate for 50 min in the dark.
Counterstaining was done with hematoxylin. Positive controls
included archived EBOV-infected cynomolgus tissue, and negative
controls included replicate sections exposed to anti-Marburg virus
antibodies and uninfected cynomolgus macaque tissue [15].
Acknowledgments
We are grateful to Ann Hessell and Paul Carney for antibody
production.
Author contributions. TWG, PBJ, PWHIP, and DRB conceived and
designed the experiments. TWG, KJD, JBG, NJS, PBJ, and PWHIP
performed the experiments. WBO, TWG, PBJ, PWHIP, and DRB
analyzed the data. TWG, KJD, and NJS contributed reagents/
materials/analysis tools. WBO and DRB wrote the paper.
Funding. This work was supported in part by grant A148053 from
the US National Institutes of Health.
Competing interests. The authors have declared that no competing
interests exist.
References
1. Casadevall A, Scharff MD (1995) Return to the past: The case for antibody-
based therapies in infectious diseases. Clin Infect Dis 21: 150–161.
2. Parren PW, Burton DR (2001) The antiviral activity of antibodies in vitro
and in vivo. Advan Immunol 77: 195–262.
3. Hangartner L, Zinkernagel RM, Hengartner H (2006) Antiviral antibody
responses: The two extremes of a wide spectrum. Nat Rev Immunol 6: 231–
243.
4. Guillaume V, Contamin H, Loth P, Grosjean I, Courbot MC, et al. (2006)
Antibody prophylaxis and therapy against Nipah virus infection in
hamsters. J Virol 80: 1972–1978.
5. Seiler P, Brundler MA, Zimmermann C, Weibel D, Bruns M, et al. (1998)
Induction of protective cytotoxic T-cell responses in the presence of high
titers of virus-neutralizing antibodies: Implications for passive and active
immunization. J Exp Med 187: 649–654.
6. Parren PW, Geisbert TW, Maruyama T, Jahrling PB, Burton DR (2002) Pre-
and post-exposure prophylaxis of Ebola virus infection in an animal model
by passive transfer of a neutralizing human antibody. J Virol 76: 6408–6412.
7. Burton DR (2002) Antibodies, viruses, and vaccines. Nat Rev Immunol 2:
706–713.
8. Sanchez A, Khan AS, Zaki SR, Nabel GJ, Ksiazek TG, et al. (2001) Filoviridae:
Marburg and Ebola viruses. In: Knipe DM, Howley PM, editors. Fields
virology. Philadelphia: Lippincott, Williams, and Wilkins. pp. 1279–1304.
9. World Health Organization (2004) Ebola haemorrhagic fever. Geneva:
World Health Organization. Available: http://www.who.int/mediacentre/
factsheets/fs103/en/. Accessed 21 December 2006.
10. Mupapa K, Massamba M, Kibadi K, Kuvula K, Bwaka A, et al. (1999)
Treatment of Ebola hemorrhagic fever with blood transfusions from
convalescent patients. J Infect Dis 179 (Suppl 1): S18–S23.
11. Maruyama T, Rodriguez LL, Jahrling PB, Sanchez A, Khan AS, et al. (1999)
Ebola virus can be effectively neutralized by antibody produced in natural
human infection. J Virol 73: 6024–6030.
12. Jahrling PB, Geisbert J, Swearengen JR, Jaax GP, Lewis T, et al. (1996)
Passive immunization of Ebola virus-infected cynomolgus monkeys with
immunoglobulin from hyperimmune horses. Arch Virol 11: 135–140.
13. Jahrling PB, Geisbert TW, Geisbert JB, Swearengen JR, Bray M, et al. (1999)
Evaluation of immune globulin and recombinant interferon-alpha2b for
treatment of experimental Ebola virus infections. J Infect Dis 179 (Suppl 1):
S224–S234.
14. Geisbert TW, Hensley LE, Geisbert JB, Jahrling PB (2002) Evidence against
an important role for infectivity-enhancing antibodies in Ebola virus
infections. Virology 293: 15–19.
15. Geisbert TW, Young HA, Jahrling PB, Davis KJ, Larsen T, et al. (2003)
Pathogenesis of Ebola hemorrhagic fever in primate models: Evidence that
hemorrhage is not a direct effect of virus-induced cytolysis of endothelial
cells. Am J Pathol 163: 2371–2382.
16. Geisbert TW, Hensley LE, Jahrling PB, Larsen T, Geisbert JB, et al. (2003)
Treatment of Ebola virus infection with a recombinant inhibitor of factor
VIIa/tissue factor: A study in rhesus monkeys. Lancet 362: 1953–1958.
17. Borisevich IV, Mikhailov VV, Krasnianskii VP, Gradoboev VN, Lebedin-
skaia EV, et al. (1995) Development and study of the properties of
immunoglobulin against Ebola fever. Vopr Virusol 40: 270–273.
18. Kudoyarova-Zubavichene NM, Sergeyev NN, Chepurnov AA, Netesov SV
(1999) Preparation and use of hyperimmune serum for prophylaxis and
therapy of Ebola virus infections. J Infect Dis 179 (Suppl 1): S218–S223.
19. Markin VA, Mikhailov VV, Krasnianskii VP, Borisevich IV, Firsova IV (1997)
Developing principles for emergency prevention and treatment of Ebola
fever. Vopr Virusol 42: 31–34.
20. Greenough TC, Babcock GJ, Roberts A, Hernandez HJ, Thomas WD Jr, et al.
(2005) Development and characterization of a severe acute respiratory
syndrome-associated coronavirus-neutralizing human monoclonal anti-
body that provides effective immunoprophylaxis in mice. J Infect Dis 191:
507–514.
21. Connolly BM, Steele KE, Davis KJ, Geisbert TW, Kell WM, et al. (1999)
Pathogenesis of experimental Ebola virus infection in guinea pigs. J Infect
Dis 179 (Suppl 1): S203–S217.
22. Ryabchikova EI, Kolesnikova LV, Luchko SV (1999) An analysis of features
of pathogenesis in two animal models of Ebola virus infection. J Infect Dis
179 (Suppl 1): S199–S202.
23. Schnittler HJ, Feldmann H (1998) Marburg and Ebola hemorrhagic fevers:
Does the primary course of infection depend on the accessibility of organ-
speciﬁc macrophages? Clin Infect Dis 27: 404–406.
24. Schnittler HJ, Feldmann H (1999) Molecular pathogenesis of ﬁlovirus
infections: Role of macrophages and endothelial cells. Curr Top Microbiol
Immunol 235: 175–204.
25. Lekkerkerker AN, van Kooyk Y, Geijtenbeek TB (2006) Viral piracy: HIV-1
targets dendritic cells for transmission. Curr HIV Res 4: 169–176.
26. Jones SM, Feldmann H, Stroher U, Geisbert JB, Fernando L, et al. (2005)
Live attenuated recombinant vaccine protects nonhuman primates against
Ebola and Marburg viruses. Nat Med 11: 786–790.
27. Sullivan NJ, Geisbert TW, Geisbert JB, Xu L, Yang ZY, et al. (2003)
Accelerated vaccination for Ebola virus haemorrhagic fever in nonhuman
primates. Nature 424: 681–684.
28. National Research Council (1996) Guide for the care and use of laboratory
animals. Washington (D. C.): Washington Academy Press. 125 p.
29. Parren PW, Marx PA, Hessell AJ, Luckay A, Harouse J, et al. (2001) Antibody
protects macaques against vaginal challenge with a pathogenic R5 simian/
human immunodeﬁciency virus at serum levels giving complete neutraliza-
tion in vitro. J Virol 75: 8340–8347.
30. Jahrling PB, Hesse RA, Eddy GA, Johnson KM, Callis RT, et al. (1980) Lassa
virus infection of rhesus monkeys: Pathogenesis and treatment with
ribavirin. J Infect Dis 141: 580–589.
PLoS Pathogens | www.plospathogens.org January 2007 | Volume 3 | Issue 1 | e9 0066
Anti-Ebola Antibody Activity In Vivo